We present a review of the association between COVID-19 and autoimmune diseases,
focusing on similarities in immune responses, cross-reactivity of SARS-CoV-2, the …

Abstract Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2) has posed a significant threat to global health. This …

Objective To determine whether tocilizumab improves clinical outcomes for patients with
severe or critical coronavirus disease 2019 (covid-19). Design Randomised, open label trial …

Introducción: La pandemia por SARS-Cov-2 ha tenido un impacto negativo en múltiples
aspectos de la vida humana, tanto en lo físico, psicológico, económico, social y cultural. Las …

Cytokine storm syndrome (CSS) is a severe complication of inflammatory immune diseases
or treatment of malignancies; it may also appear during the progression of COVID-19. CSS …

The efficacy of tocilizumab (TOC), monoclonal antibody against interleukin‐6 (IL‐6) receptor,
in patients with coronavirus disease‐2019 (COVID‐19) patients has led to conflicting results …

As the pandemic progresses, the pathophysiology of coronavirus disease 2019 (COVID‐19)
is becoming clearer and the potential for immunotherapy is increasing. However, clinical …

Background There is accumulating evidence for an overly activated immune response in
severe COVID-19, with several studies exploring the therapeutic role of immunomodulation …

Background The COVID-19 outbreak challenges the Spanish health system since March
2020. Some available therapies (antimalarials, antivirals, biological agents) were grounded …

Introduction Current evidence indicates that smoking worsens COVID-19 outcomes.
However, when studies restricted their analyses to current smokers, the risks for COVID-19 …